The ROE as of November 2024 (TTM) for Humacyte, Inc. (HUMA) is 1.17%

According to Humacyte, Inc.’s latest financial reports and current stock price. The company's current ROE is 1.17%. This represents a change of -10383.82% compared to the average of -11.37% of the last 4 quarters.

Humacyte, Inc. (HUMA) Historical ROE (quarterly & annually)

How has HUMA ROE performed in the past?

The mean historical ROE of Humacyte, Inc. over the last ten years is -155.43%. The current 1.17% ROE has changed -852.08% with respect to the historical average. Over the past ten years (40 quarters), HUMA's ROE was at its highest in in the June 2020 quarter at 1.69%. The ROE was at its lowest in in the March 2021 quarter at -406.02%.

Humacyte, Inc. (HUMA) ROE by Quarter and Year

Discovering the peaks and valleys of Humacyte, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Humacyte, Inc. (HUMA) Average ROE

How has HUMA ROE performed in the past?

The current ROE of Humacyte, Inc. (HUMA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Humacyte, Inc. (HUMA) ROE vs. Peers

How is HUMA’s ROE compared to its peers?

Humacyte, Inc.’s ROE is greater than Crinetics Pharmaceuticals, Inc. (-36.12%), greater than Viridian Therapeutics, Inc. (-45.47%), less than Cytokinetics, Incorporated (335.19%), greater than Structure Therapeutics Inc. (-16.40%), greater than Icosavax, Inc. (-20.22%), greater than Immunocore Holdings plc (-14.67%), greater than Mirum Pharmaceuticals, Inc. (-41.22%), greater than Larimar Therapeutics, Inc. (-35.87%), greater than KalVista Pharmaceuticals, Inc. (-97.37%), greater than Lyra Therapeutics, Inc. (-178.68%), greater than Theseus Pharmaceuticals, Inc. (-12.35%), greater than Kura Oncology, Inc. (-44.09%), greater than Nurix Therapeutics, Inc. (-63.39%), greater than Seer, Inc. (-22.19%), greater than Quantum-Si incorporated (-37.12%), greater than HCW Biologics Inc. (-2516.87%), greater than MediciNova, Inc. (-20.70%),

Build a custom stock screener for Humacyte, Inc. (HUMA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Humacyte, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Humacyte, Inc. (HUMA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Humacyte, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.